Home

Axsome Therapeutics, Inc. - Common Stock (AXSM)

111.60
-0.31 (-0.28%)
NASDAQ · Last Trade: Jun 9th, 11:11 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close111.91
Open110.50
Bid111.20
Ask111.63
Day's Range108.23 - 112.92
52 Week Range64.11 - 139.13
Volume324,870
Market Cap5.27B
PE Ratio (TTM)-19.34
EPS (TTM)-5.8
Dividend & YieldN/A (N/A)
1 Month Average Volume619,375

Chart

About Axsome Therapeutics, Inc. - Common Stock (AXSM)

Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of central nervous system (CNS) disorders. The company’s research is centered on addressing some of the most challenging conditions in mental health and neurological disorders, including depression, migraine, and Alzheimer’s disease. Axsome is dedicated to advancing its pipeline of drug candidates through rigorous clinical trials with the goal of providing new and effective treatment options to patients and improving their quality of life. Through its commitment to science and patient care, Axsome aims to make significant contributions to the field of CNS therapeutics. Read More

News & Press Releases

Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviewsbenzinga.com
Via Benzinga · June 9, 2025
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitabilitystocktwits.com
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.
Via Stocktwits · June 9, 2025
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · June 9, 2025
2 Soaring Stocks Wth More Upside Potentialfool.com
Via The Motley Fool · June 5, 2025
Earnings Scheduled For May 5, 2025benzinga.com
Via Benzinga · May 5, 2025
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June:
By Axsome Therapeutics, Inc. · Via GlobeNewswire · May 29, 2025
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations from three of its innovative neuroscience programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting, being held from May 27-30 in Scottsdale, Arizona.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · May 28, 2025
Why Is Teva Stock Trading Higher On Tuesday?benzinga.com
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Via Benzinga · May 27, 2025
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Hetero a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · May 27, 2025
3 High-Flying Stocks That Could Soar Even Morefool.com
Via The Motley Fool · May 24, 2025
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analystsbenzinga.com
Via Benzinga · May 22, 2025
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysisfool.com
Via The Motley Fool · May 14, 2025
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
Previous term loan facility retired
By Axsome Therapeutics, Inc. · Via GlobeNewswire · May 13, 2025
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Yearsfool.com
Via The Motley Fool · May 12, 2025
3 Monster Stocks in the Makingfool.com
Via The Motley Fool · May 11, 2025
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1benzinga.com
Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.
Via Benzinga · May 5, 2025
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth
By Axsome Therapeutics, Inc. · Via GlobeNewswire · May 5, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May’s Mental Health Month.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · May 1, 2025
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)benzinga.com
Via Benzinga · April 29, 2025
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May:
By Axsome Therapeutics, Inc. · Via GlobeNewswire · April 22, 2025
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)
PHILADELPHIA, April 14, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 14, 2025
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates
PHILADELPHIA , April 11, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 11, 2025
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
PHILADELPHIA, April 08, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 8, 2025
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · April 8, 2025
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · April 7, 2025